Remed Co.,Ltd. (KOSDAQ:302550)
South Korea
· Delayed Price · Currency is KRW 3,130.00
-25.00 (-0.79%)
At close: Mar 21, 2025, 3:30 PM KST
Remed Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Operating Revenue | 25,554 | 18,536 | 21,363 | 20,195 | 16,633 | Upgrade
|
| Other Revenue | -0 | - | - | -0 | - | Upgrade
|
| Revenue | 25,554 | 18,536 | 21,363 | 20,195 | 16,633 | Upgrade
|
| Revenue Growth (YoY) | 37.86% | -13.23% | 5.79% | 21.41% | -10.33% | Upgrade
|
| Cost of Revenue | 11,508 | 9,589 | 10,293 | 9,880 | 8,057 | Upgrade
|
| Gross Profit | 14,046 | 8,947 | 11,071 | 10,315 | 8,576 | Upgrade
|
| Selling, General & Admin | 8,422 | 7,949 | 6,593 | 5,711 | 4,243 | Upgrade
|
| Research & Development | 3,483 | 2,940 | 2,426 | 2,731 | 2,288 | Upgrade
|
| Other Operating Expenses | 93.38 | 97.1 | 88.47 | 53.18 | 143.28 | Upgrade
|
| Operating Expenses | 12,925 | 11,807 | 9,410 | 9,192 | 6,892 | Upgrade
|
| Operating Income | 1,121 | -2,860 | 1,661 | 1,123 | 1,684 | Upgrade
|
| Interest Expense | -1,174 | -1,244 | -966.8 | -775.51 | -416.03 | Upgrade
|
| Interest & Investment Income | 444.54 | 847.53 | 687.73 | 706.26 | 232.96 | Upgrade
|
| Earnings From Equity Investments | -105.74 | -150.16 | -111.99 | -100.22 | -90.73 | Upgrade
|
| Currency Exchange Gain (Loss) | 668.74 | 334.91 | 272.88 | 542.56 | -701.49 | Upgrade
|
| Other Non Operating Income (Expenses) | 3,304 | -283.26 | 3,424 | -576.44 | -3,000 | Upgrade
|
| EBT Excluding Unusual Items | 4,259 | -3,355 | 4,967 | 919.81 | -2,291 | Upgrade
|
| Impairment of Goodwill | -268.88 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -343.93 | 342.47 | -336.6 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 4,400 | -0.01 | -70.63 | -36.72 | 11.92 | Upgrade
|
| Other Unusual Items | - | 3,992 | - | - | - | Upgrade
|
| Pretax Income | 8,045 | 979.66 | 4,560 | 883.08 | -2,279 | Upgrade
|
| Income Tax Expense | 664.59 | 660.41 | 608.71 | 130.75 | -445.46 | Upgrade
|
| Earnings From Continuing Operations | 7,381 | 319.24 | 3,951 | 752.33 | -1,834 | Upgrade
|
| Minority Interest in Earnings | -208.68 | 477.92 | 48.88 | - | - | Upgrade
|
| Net Income | 7,172 | 797.17 | 4,000 | 752.33 | -1,834 | Upgrade
|
| Net Income to Common | 7,172 | 797.17 | 4,000 | 752.33 | -1,834 | Upgrade
|
| Net Income Growth | 799.69% | -80.07% | 431.70% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 31 | 31 | 31 | 31 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 32 | 31 | 31 | 31 | 30 | Upgrade
|
| Shares Change (YoY) | 4.90% | 0.07% | 0.35% | 1.84% | 14.35% | Upgrade
|
| EPS (Basic) | 234.00 | 26.00 | 130.56 | 24.64 | -61.17 | Upgrade
|
| EPS (Diluted) | 223.00 | 26.00 | 130.56 | 24.60 | -61.20 | Upgrade
|
| EPS Growth | 757.69% | -80.09% | 430.73% | - | - | Upgrade
|
| Free Cash Flow | 658.57 | 2,708 | 261.1 | -7,431 | 1,911 | Upgrade
|
| Free Cash Flow Per Share | 20.48 | 88.33 | 8.52 | -243.41 | 63.75 | Upgrade
|
| Gross Margin | 54.97% | 48.27% | 51.82% | 51.08% | 51.56% | Upgrade
|
| Operating Margin | 4.39% | -15.43% | 7.78% | 5.56% | 10.12% | Upgrade
|
| Profit Margin | 28.07% | 4.30% | 18.72% | 3.72% | -11.03% | Upgrade
|
| Free Cash Flow Margin | 2.58% | 14.61% | 1.22% | -36.80% | 11.49% | Upgrade
|
| EBITDA | 2,399 | -1,905 | 2,417 | 1,684 | 2,079 | Upgrade
|
| EBITDA Margin | 9.39% | -10.28% | 11.31% | 8.34% | 12.50% | Upgrade
|
| D&A For EBITDA | 1,278 | 954.51 | 755.6 | 560.7 | 395.47 | Upgrade
|
| EBIT | 1,121 | -2,860 | 1,661 | 1,123 | 1,684 | Upgrade
|
| EBIT Margin | 4.39% | -15.43% | 7.78% | 5.56% | 10.12% | Upgrade
|
| Effective Tax Rate | 8.26% | 67.41% | 13.35% | 14.81% | - | Upgrade
|
| Advertising Expenses | 535.11 | 725.79 | 420.15 | 299.26 | 70.05 | Upgrade
|
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.